Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

Li T, Wang B, Wang Z, Ragaz J, Zhang J, Sun S, Cao J, Lv F, Wang L, Zhang S, Ni C, Wu Z, Xie J, Hu X.

PLoS One. 2015 Jul 17;10(7):e0133133. doi: 10.1371/journal.pone.0133133. eCollection 2015.

2.

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM.

Lancet Oncol. 2015 Apr;16(4):436-46. doi: 10.1016/S1470-2045(15)70064-1. Epub 2015 Mar 18.

PMID:
25795409
3.

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, Fan M, Li J, Wang B, Wang Z, Zhang Q, Sun S, Liao C.

Int J Cancer. 2014 Oct 15;135(8):1961-9. doi: 10.1002/ijc.28829. Epub 2014 Mar 20.

4.

The SUVmax for (18)F-FDG correlates with molecular subtype and survival of previously untreated metastatic breast cancer.

Zhang J, Jia Z, Zhou M, Ragaz J, Zhang YP, Wang BY, Wang ZH, Hu XC, Zhang YJ.

Clin Nucl Med. 2013 Apr;38(4):256-62. doi: 10.1097/RLU.0b013e3182816318.

PMID:
23429396
5.

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer.

Zhang J, Jia Z, Ragaz J, Zhang YJ, Zhou M, Zhang YP, Li G, Wang BY, Wang ZH, Hu XC.

BMC Cancer. 2013 Jan 31;13:42. doi: 10.1186/1471-2407-13-42.

6.

Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

Ragaz J.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S14. doi: 10.1186/bcr2743. No abstract available.

7.

Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.

Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X.

Breast Cancer Res Treat. 2010 Dec;124(3):733-43. doi: 10.1007/s10549-010-1183-6. Epub 2010 Sep 30.

PMID:
20882405
8.

Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival.

Woodward WA, Truong PT, Yu TK, Tereffe W, Oh J, Perkins G, Strom E, Meric-Bernstam F, Gonzalez-Angulo AM, Speers C, Ragaz J, Buchholz TA.

Breast Cancer Res Treat. 2010 Sep;123(2):597-605. doi: 10.1007/s10549-010-0829-8. Epub 2010 Mar 20.

9.

Radiation impact in breast cancer.

Ragaz J.

Breast Cancer Res. 2009;11 Suppl 3:S14. doi: 10.1186/bcr2433. Epub 2009 Dec 18. Review. No abstract available.

10.

Adjuvant targeted therapy in early breast cancer.

Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Pritchard K, Laing K, Provencher L, Charbonneau LF.

Cancer. 2009 Mar 15;115(6):1154-68. doi: 10.1002/cncr.24114. Review.

12.

Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.

Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C.

Clin Cancer Res. 2006 Apr 15;12(8):2468-75. Erratum in: Clin Cancer Res. 2006 Aug 15;12(16):5002.

13.

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M.

J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.

PMID:
15657341
14.

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM.

Clin Cancer Res. 2004 Aug 15;10(16):5367-74.

15.

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM.

J Natl Cancer Inst. 2004 Mar 17;96(6):456-65.

PMID:
15026471
16.

Dose density by any other name.

Hryniuk W, Ragaz J, Peters W.

J Clin Oncol. 2004 Feb 15;22(4):750-1; author reply 751-3. No abstract available.

PMID:
14966105
17.

Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.

Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE.

Cancer Res. 2004 Jan 1;64(1):286-91.

18.

Increased use of adjuvant regional radiotherapy for node-positive breast cancer in British Columbia.

Chua B, Olivotto IA, Weir L, Kwan W, Truong P, Ragaz J.

Breast J. 2004 Jan-Feb;10(1):38-44.

PMID:
14717758
19.

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T.

Cell. 2003 Nov 26;115(5):523-35.

20.

Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer.

Bryce C, Kennecke H, Chia S, Ragaz J.

J Clin Oncol. 2003 Dec 1;21(23):4465; author reply 4465-6. No abstract available.

PMID:
14645445
21.

Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer.

Olivotto IA, Chua B, Allan SJ, Speers CH, Chia S, Ragaz J.

J Clin Oncol. 2003 Mar 1;21(5):851-4. Epub 2003 Mar 1.

PMID:
12610184
22.

Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy.

Ragaz J.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):133-41. Review.

PMID:
11850217
23.

Breast cancer survival advantage with radiotherapy.

Ragaz J, Spinelli JJ, Coldman AJ.

Lancet. 2000 Oct 7;356(9237):1270; author reply 1271. No abstract available.

PMID:
11072966
24.

Wide-field radiation as adjunct to adjuvant chemotherapy in high-risk cases with early breast cancer: do it or not?

Ragaz J, Spinelli JJ.

Int J Cancer. 2000 Aug 1;87(3):423-6. No abstract available.

25.

Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation.

Ragaz J, Jackson SM.

Cancer. 2000 Jul 1;89(1):223-5. No abstract available.

PMID:
10897026
26.

A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma.

Jackson JS, Olivotto IA, Wai M D E, Grau C, Mates D, Ragaz J.

Cancer. 2000 Apr 15;88(8):1852-62.

PMID:
10760762
27.

Status of aromatase inhibitors in relation to other breast cancer treatment modalities.

Ragaz J.

Endocr Relat Cancer. 1999 Jun;6(2):277-91. Review.

PMID:
10731121
28.

Large breast cancer tumors and radiotherapy: biology vs. chronology.

Ragaz J, Spinelli JJ.

Radiother Oncol. 1999 Sep;52(3):203-5. No abstract available.

PMID:
10580864
29.

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

Gelmon KA, Tolcher A, O'Reilly S, Campbell C, Bryce C, Shenkier T, Ragaz J, Ayers D, Nakashima L, Rielly S, Dulude H.

Ann Oncol. 1998 Nov;9(11):1247-9.

PMID:
9862057
30.

Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis.

Olivotto IA, Jackson JS, Mates D, Andersen S, Davidson W, Bryce CJ, Ragaz J.

Cancer. 1998 Sep 1;83(5):948-55.

PMID:
9731899
32.

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wilson KS, Knowling MA, Coppin CM, Paradis M, Coldman AJ, Olivotto IA.

N Engl J Med. 1997 Oct 2;337(14):956-62.

33.

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.

Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA.

J Clin Oncol. 1997 Jun;15(6):2302-11.

PMID:
9196144
34.

Interaction of tamoxifen's impact on overall net mortality and quality of life.

Ragaz J.

Oncology (Williston Park). 1997 Feb;11(2 Suppl 1):45-8. Review.

35.

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.

Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C, Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healey D, Onetto N.

J Clin Oncol. 1996 Apr;14(4):1185-91.

PMID:
8648373
36.

Adjuvant systemic therapy and survival after breast cancer.

Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A.

N Engl J Med. 1994 Mar 24;330(12):805-10.

37.
38.

Ventricular arrhythmia and adrenal insufficiency after fluorouracil: new side effects of an old drug.

Harris LN, Ragaz J.

J Natl Cancer Inst. 1993 Feb 17;85(4):326-8. No abstract available.

PMID:
8426375
39.

Psychosocial and Physical Effects of Adjuvant Chemotherapy: Survey of younger women with breast cancer.

Hislop TG, Elwood JM, Waxler-Morrison N, Ragaz J, Skippen DH, Turner ID.

Can Fam Physician. 1991 May;37:1137-44.

41.

Chemotherapy and hormonal therapy in stage III disease; inflammatory breast cancer.

Ragaz J.

Curr Opin Oncol. 1990 Dec;2(6):1068-87. Review. No abstract available.

PMID:
2099838
42.

Biologic aspects, classification, surgery, and radiotherapy of stage III breast cancer.

Ragaz J.

Curr Opin Oncol. 1990 Dec;2(6):1053-67. Review. No abstract available.

PMID:
2099837
43.
44.

Questions related to the effects of therapy on biology and kinetics of the surviving tumor.

Ragaz J, Simpson-Herren L, Lippman M, Fisher B.

Prog Clin Biol Res. 1990;354A:1-6. No abstract available.

PMID:
2247483
45.
46.

Comments on kinetics and biology of the residual cancer, and on relevant therapeutic strategies based on these phenomena.

Ragaz J.

Prog Clin Biol Res. 1990;354B:117-39. Review. No abstract available.

PMID:
2236161
47.

Experimental basis and clinical reality of preoperative (neoadjuvant) chemotherapy in breast cancer.

Ragaz J, Goldie JH, Baird R, Rebbeck P, Basco V, Coldman A.

Recent Results Cancer Res. 1989;115:28-35. No abstract available.

PMID:
2623337
48.

Hepatocellular carcinoma. A comparison of Oriental and Caucasian patients.

Scudamore CH, Ragaz J, Kluftinger AM, Owen DA.

Am J Surg. 1988 May;155(5):659-62.

PMID:
2453124
49.
50.

Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia Trial.

Ragaz J.

Recent Results Cancer Res. 1986;103:85-94. No abstract available.

PMID:
3526477

Supplemental Content

Support Center